Latest Period
Q4 2025
Security Snapshot
Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) Institutional Ownership
CUSIP: 03836J201
13F Institutional Holders and Ownership History from Q1 2023 to Q1 2026
Institutions Reporting
22
Shares (Excl. Options)
1,695,512
Price
$0.85
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common stock, par value $0.001 per share
- Symbol
- APRE on Nasdaq
- Shares outstanding
- 9,144,889
- Price per share
- $0.85
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 1,695,512
- Total reported value
- $1,446,275
- % of total 13F portfolios
- 0%
- Share change
- +66,461
- Value change
- -$113,007
- Number of holders
- 22
- Price from insider filings
- $0.85
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share is tracked under CUSIP 03836J201.
- 22 institutions reported positions in Q4 2025.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 22 to 5 between Q4 2025 and Q1 2026.
- Reported value moved from $1,446,275 to $803,050.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 22 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 03836J201?
CUSIP 03836J201 identifies APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03836J201:
Significant Owners of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| LYTTON LAURENCE W | 9.9% | $913,662 | 681,837 | LYTTON LAURENCE W | 13 Nov 2025 | |||
| Nantahala Capital Management, LLC | 4.5% | -40% | $386,829 | 411,520 | 0% | Nantahala Capital Management, LLC | 31 Dec 2025 | |
| Stonepine Capital Management, LLC | 4.3% | -16% | $418,978 | -$82,213 | 239,416 | -16% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| Sio Capital Management, LLC | 1.9% | -62% | $165,529 | -$246,540 | 112,223 | -60% | Sio Capital Management, LLC | 30 Sep 2025 |
As of 31 Dec 2025, 22 institutional investors reported holding 1,695,512 shares of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE). This represents 19% of the company’s total 9,144,889 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) together control 19% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| AIGH Capital Management LLC | 4.1% | 370,541 | -31% | 0.09% | $316,071 |
| Murchinson Ltd. | 3.7% | 340,139 | 0.18% | $290,139 | |
| SPHERA FUNDS MANAGEMENT LTD. | 3% | 270,000 | 0% | 0.05% | $230,310 |
| Nantahala Capital Management, LLC | 2.2% | 205,760 | 0% | 0.01% | $175,513 |
| DRW Securities, LLC | 1.3% | 120,651 | 0.01% | $102,915 | |
| MORGAN STANLEY | 0.84% | 77,030 | +17% | 0% | $65,706 |
| VANGUARD GROUP INC | 0.64% | 58,086 | -63% | 0% | $49,548 |
| CITADEL ADVISORS LLC | 0.56% | 51,041 | 0% | $43,538 | |
| JANE STREET GROUP, LLC | 0.51% | 46,621 | 0% | $39,767 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.45% | 40,950 | -8.2% | 0% | $34,935 |
| BNP PARIBAS FINANCIAL MARKETS | 0.3% | 27,332 | 0% | 0% | $23,314 |
| LPL Financial LLC | 0.28% | 26,052 | +62% | 0% | $22,222 |
| XTX Topco Ltd | 0.27% | 24,304 | 0% | $20,731 | |
| HighTower Advisors, LLC | 0.15% | 13,864 | 0% | 0% | $11,826 |
| BlackRock, Inc. | 0.09% | 8,504 | 0% | 0% | $7,255 |
| Tower Research Capital LLC (TRC) | 0.09% | 7,827 | +1278% | 0% | $6,676 |
| BANK OF AMERICA CORP /DE/ | 0.04% | 3,299 | -32% | 0% | $2,814 |
| UBS Group AG | 0.03% | 2,461 | +81933% | 0% | $2,100 |
| GROUP ONE TRADING LLC | 0.01% | 577 | 0% | 0% | $492 |
| OSAIC HOLDINGS, INC. | 0% | 300 | -25% | 0% | $255 |
| WealthCollab, LLC | 0% | 158 | 0% | 0% | $135 |
| SBI Securities Co., Ltd. | 0% | 15 | -64% | 0% | $13 |
| Sio Capital Management, LLC | 0% | 0 | -100% | $0 | |
| MB, LEVIS & ASSOCIATES, LLC | 0% | 0 | -100% | $0 | |
| CITIGROUP INC | 0% | 0 | -100% | $0 |
Institutional Holders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 1,052,626 | $803,050 | +$488,022 | $0.76 | 5 |
| 2025 Q4 | 1,695,512 | $1,446,275 | -$113,007 | $0.85 | 22 |
| 2025 Q3 | 1,618,851 | $2,387,744 | -$296,033 | $1.48 | 23 |
| 2025 Q2 | 1,815,508 | $3,072,270 | -$77,601 | $1.69 | 23 |
| 2025 Q1 | 1,847,462 | $3,768,839 | -$165,845 | $2.04 | 25 |
| 2024 Q4 | 2,077,381 | $6,829,282 | +$211,103 | $3.29 | 26 |
| 2024 Q3 | 2,000,189 | $5,500,414 | -$431,314 | $2.75 | 21 |
| 2024 Q2 | 2,083,045 | $8,477,419 | +$1,866,030 | $4.07 | 27 |
| 2024 Q1 | 1,624,394 | $10,764,195 | +$4,966,764 | $6.69 | 22 |
| 2023 Q4 | 926,780 | $4,355,977 | +$26,645 | $4.70 | 19 |
| 2023 Q3 | 876,935 | $3,660,270 | -$19,509 | $4.17 | 19 |
| 2023 Q2 | 881,553 | $2,776,892 | +$105,033 | $3.15 | 17 |
| 2023 Q1 | 848,237 | $3,769,266 | +$3,769,266 | $4.44 | 15 |